Building the bridge from bench to bedside | PDF (585 KB)

p463 | doi:10.1038/nrd2609

Neurodegenerative disease: Inhibiting -secretase where it matters | PDF (399 KB)

p475 | doi:10.1038/nrd2597

Neurodegenerative disease: A new pathway to autophagy | PDF (425 KB)

p476 | doi:10.1038/nrd2598

Cardiovascular disease: Novel antibody blocks thrombus formation | PDF (402 KB)

p476 | doi:10.1038/nrd2601

Molecularly targeted therapy: JAK2 inhibitor restores balance in polycythaemia vera | PDF (210 KB)

p477 | doi:10.1038/nrd2599

Stem cells: Boosting myocardial repair | PDF (364 KB)

p478 | doi:10.1038/nrd2600

Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets

Masato Furuhashi & Gökhan S. Hotamisligil

p489 | doi:10.1038/nrd2589

Fatty acid-binding proteins (FABPs) are members of a highly conserved family of proteins central to lipid-mediated processes and related metabolic and immune response pathways. Here, the authors review the functions of individual FABP family members, emphasizing the potential of FABP inhibition as a novel strategy in the treatment of disorders of the metabolic syndrome including obesity, diabetes and atherosclerosis.

• Abstract
• Full Text
• PDF (1,392 KB)

Drug development of MET inhibitors: targeting oncogene addiction and expedience

Paolo M. Comoglio, Silvia Giordano & Livio Trusolino

p504 | doi:10.1038/nrd2530

MET tyrosine kinase has a central role in cell motility, proliferation and protection from apoptosis — properties that can transform it into a powerful pro-metastatic agent or oncogene. Here, Comoglio and colleagues discuss its biological role in cancer progression, recent progress in MET-targeted therapies, and how to identify the patient populations that might benefit from such treatment.

• Abstract
• Full Text
• PDF (573 KB)

Form to function: current and future roles for atherosclerosis imaging in drug development

Alistair C. Lindsay & Robin P. Choudhury

p517 | doi:10.1038/nrd2588

Successful development of novel anti-atherosclerosis therapies is hampered by the lack of imaging biomarkers for their evaluation. In their article, Lindsay and Choudhury compare and contrast the ability of current atherosclerosis imaging modalities to predict clinical outcomes and discuss the potential of emerging technologies to aid anti-atherosclerosis drug development by quantifying changes in biological function at the level of the atherosclerotic plaque.

• Abstract
• Full Text
• PDF (1,297 KB)

Emerging anti-insomnia drugs: tackling sleeplessness and the quality of wake time

Keith A. Wafford & Bjarke Ebert

p530 | doi:10.1038/nrd2464

In this Review Ebert and Wafford discuss the mechanisms of action of current and emerging hypnotic drugs, emphasizing the importance of taking into account the consequences of disrupted sleep on day-time performance (or quality of wakefulness) when developing new therapeutics.

• Abstract
• Full Text
• PDF (799 KB)

Venture capital

p541 | doi:10.1038/nrd2604

• Abstract
• Full Text
• PDF (251 KB)